Related Experiment Video
Updated: Sep 23, 2025
Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
Published on: August 5, 2021
Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies
Wanqin Liu1, Shanshan Liu1, Ping Li1
1Institute of Visual Neuroscience and Stem Cell Engineering, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan 430065, China.
Abstract:
Retinitis pigmentosa (RP) is genetically heterogeneous retinopathy caused by photoreceptor cell death and retinal pigment epithelial atrophy that eventually results in blindness in bilateral eyes. Various photoreceptor cell death types and pathological phenotypic changes that have been disclosed in RP demand in-depth research of its pathogenic mechanism that may account for inter-patient heterogeneous responses to mainstream drug treatment. As the primary method for studying the genetic characteristics of RP, molecular biology has been widely used in disease diagnosis and clinical trials. Current technology iterations, such as gene therapy, stem cell therapy, and optogenetics, are advancing towards precise diagnosis and clinical applications. Specifically, technologies, such as effective delivery vectors, CRISPR/Cas9 technology, and iPSC-based cell transplantation, hasten the pace of personalized precision medicine in RP. The combination of conventional therapy and state-of-the-art medication is promising in revolutionizing RP treatment strategies. This article provides an overview of the latest research on the pathogenesis, diagnosis, and treatment of retinitis pigmentosa, aiming for a convenient reference of what has been achieved so far.
Insights
Retinitis pigmentosa (RP) is a blinding eye disease with complex causes. Recent advances in gene therapy, stem cells, and optogenetics offer new hope for personalized treatments.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Retinitis pigmentosa (RP) is a genetically diverse condition leading to photoreceptor cell death and vision loss.
- Understanding RP's varied mechanisms is crucial for effective, individualized drug treatments.
- Current research highlights the need for advanced diagnostic and therapeutic approaches.
Purpose of the Study:
- To provide a comprehensive overview of the latest research in retinitis pigmentosa.
- To summarize advancements in understanding RP pathogenesis, diagnosis, and treatment strategies.
- To serve as a reference for current achievements in RP research.
Main Methods:
- Review of molecular biology techniques for RP genetic characterization.
- Analysis of emerging technologies including gene therapy, stem cell therapy, and optogenetics.
- Examination of innovative tools like CRISPR/Cas9 and iPSC-based transplantation.
Main Results:
- Molecular biology is key to RP diagnosis and clinical trials.
- Gene therapy, stem cells, and optogenetics are advancing precise RP diagnosis and treatment.
- CRISPR/Cas9 and iPSC technology accelerate personalized medicine for RP.
Conclusions:
- The combination of conventional and novel therapies shows promise for transforming RP treatment.
- Continued research into RP pathogenesis and treatment is essential.
- Personalized precision medicine approaches are rapidly evolving for retinitis pigmentosa.
